Diagnosis of malignant portal vein infiltration and especially differentiation from bland thrombosis is challenging for most imaging techniques. The use of contrast-enhanced real-time modern imaging modalities like contrast-enhanced ultrasound (CEUS), volume perfusion CT (VPCT), or dynamic contrast-enhanced MRI (DCE-MRI) with dedicated postprocessing tools provides additional support in difficult cases and is therefore recommended.
The purpose of this review is to present a practical overview of strengths and limitations of modern imaging techniques in the diagnosis of malignant infiltration of the portal vein by hepatocellular carcinoma and to describe subsequent changes during therapy.
El-SeragHB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res2007; 37(Suppl. 2): S88–94.
2.
El-SeragHBRudolphKL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology2007; 132: 2557–2576.
3.
ParkinDMBrayFFerlayJ. Estimating the world cancer burden: Globocan 2000. Int J Cancer2001; 94: 153–156.
4.
SakataJShiraiYWakaiT. Preoperative predictors of vascular invasion in hepatocellular carcinoma. Eur J Surg Oncol2008; 34: 900–905.
5.
TakizawaDKakizakiSSoharaN. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig Dis Sci2007; 52: 3290–3295.
6.
MinagawaMMakuuchiM. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol2006; 12: 7561–7567.
7.
ZhouJTangZYWuZQ. Factors influencing survival in hepatocellular carcinoma patients with macroscopic portal vein tumor thrombosis after surgery, with special reference to time dependency: a single-center experience of 381 cases. Hepatogastroenterology2006; 53: 275–280.
8.
KimKMKimJHParkIS. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol2009; 24: 806–814.
9.
ZhaoMWangJPLiW. [Comparison of safety and efficacy for transcatheter arterial chemoembolization alone and plus radiofrequency ablation in the treatment of single branch portal vein tumor thrombus of hepatocellular carcinoma and their prognosis factors]. Zhonghua Yi Xue Za Zhi2011; 91: 1167–1172.
10.
ChoJYPaikYHParkHC. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma. Liver Int2014; 34: 795–801.
11.
KurosakiIKawachiYNiheiK. Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study. Pancreas2009; 38: 161–167.
12.
LauWYSangroBChenPJ. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology2013; 84: 311–318.
13.
MizandariMAoGZhangY. Novel percutaneous radiofrequency ablation of portal vein tumor thrombus: safety and feasibility. Cardiovasc Intervent Radiol2013; 36: 245–248.
14.
TangQHLiAJYangGM. Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study. World J Surg2013; 37: 1362–1370.
15.
YangMFangZYanZ. Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trial. J Cancer Res Clin Oncol2014; 140: 211–219.
16.
ZhaoYCaiGZhouL. Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review. Asia Pac J Clin Oncol2013; 9: 357–364.
17.
ChungJWParkJHHanJK. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. Am J Roentgenol1995; 165: 315–321.
18.
CatalanoOAChoyGZhuA. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology2010; 254: 154–162.
19.
TherassePArbuckSGEisenhauerEA. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst2000; 92: 205–216.
20.
UenoNKawamuraHTakahashiH. Characterization of portal vein thrombus with the use of contrast-enhanced sonography. J Ultrasound Med2006; 25: 1147–1152.
21.
HatanakaKKudoMMinamiY. Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology2008; 75(Suppl. 1): 42–47.
22.
RazaSAJangHJKimTK. Differentiating malignant from benign thrombosis in hepatocellular carcinoma: contrast-enhanced ultrasound. Abdom Imaging2014; 39: 153–161.
23.
TublinMEDoddGD,3rdBaronRL. Benign and malignant portal vein thrombosis: differentiation by CT characteristics. Am J Roentgenol1997; 168: 719–723.
24.
ShahZKMcKernanMGHahnPF. Enhancing and expansile portal vein thrombosis: value in the diagnosis of hepatocellular carcinoma in patients with multiple hepatic lesions. Am J Roentgenol2007; 188: 1320–1323.
25.
BotaSPiscagliaFMarinelliS. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma. Liver Cancer2012; 1: 190–200.
26.
BellomiMViottiSPredaL. Perfusion CT in solid body-tumours. Part II: Clinical applications and future development. Radiol Med2010; 115: 858–874.
27.
PetraliaGFazioNBonelloL. Perfusion computed tomography in patients with hepatocellular carcinoma treated with thalidomide: initial experience. J Comput Assist Tomogr2011; 35: 195–201.
28.
FrampasELassauNZappaM. Advanced hepatocellular carcinoma: early evaluation of response to targeted therapy and prognostic value of perfusion CT and dynamic contrast enhanced ultrasound. Preliminary results. Eur J Radiol2013; 82: e205–211.
29.
SahaniDVHolalkereNSMuellerPR. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue–initial experience. Radiology2007; 243: 736–743.
30.
FattovichGStroffoliniTZagniI. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology2004; 127: S35–50.
31.
IppolitoDCapraroCCasiraghiA. Quantitative assessment of tumour associated neovascularisation in patients with liver cirrhosis and hepatocellular carcinoma: role of dynamic-CT perfusion imaging. Eur Radiol2012; 22: 803–811.
32.
ParkJWKimJHKimSK. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med2008; 49: 1912–1921.
33.
SunLGuanYSPanWM. Highly metabolic thrombus of the portal vein: 18F fluorodeoxyglucose positron emission tomography/computer tomography demonstration and clinical significance in hepatocellular carcinoma. World J Gastroenterol2008; 14: 1212–1217.
34.
SunLGuanYSPanWM. Positron emission tomography/computer tomography in guidance of extrahepatic hepatocellular carcinoma metastasis management. World J Gastroenterol2007; 13: 5413–5415.
35.
LiCHuAHaackeM. Direct portal vein thrombosis visualization with t2*–weighted magnetic resonance imaging. Int J Med Sci2013; 10: 1570–1574.
36.
KudoM. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology2008; 75(Suppl. 1): 1–12.
37.
GranitoAGalassiMPiscagliaF. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther2013; 37: 355–363.
38.
SandrasegaranKTahirBNutakkiK. Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from benign portal vein thrombus in cirrhotic patients. Am J Roentgenol2013; 201: 1211–1219.
39.
MaksimovicOSchramlCHartmannJT. Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. Am J Roentgenol2010; 194: 5–14.
40.
HorgerMLauerUMSchramlC. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer2009; 9: 208–208.
